

EQA round: CC2/23 - Cystatin C

Deadline: 25.8.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL				
(106) Cystatin C	[mg/L]				78								78	78	100
Sample A		1,75	0,15	8,4	78		CVP	1,75	0,041	23%	1,34	2,16	78	78	100
(1) Abbott		1,87	0,1	5,6	15	0							15		
(46) Erba Lachema		1,73	0,082	4,7	5	0							5		
(60) Roche		1,64	0,031	1,9	32	0							32		
(162) Siemens (Atellica)		1,81	0,21	11	9	0							9		
(179) Siemens		1,94	0,022	1,1	5	0							5		
Other					12	0							12		
								2x 3, 2x 58, 3x 91, 1x 140, 4x 149							
Sample B		2,36	0,15	6,2	78		CVP	2,36	0,041	23%	1,81	2,91	78	78	100
(1) Abbott		2,48	0,18	7,2	15	0							15		
(46) Erba Lachema		2,33	0,11	4,8	5	0							5		
(60) Roche		2,27	0,071	3,1	32	0							32		
(162) Siemens (Atellica)		2,39	0,23	9,6	9	0							9		
(179) Siemens		2,54	0,022	0,88	5	0							5		
Other					12	0							12		
								2x 3, 2x 58, 3x 91, 1x 140, 4x 149							